• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Glob Health . Risk factors for severe COVID-19 outcomes in LATAM countries in the post-vaccination era: an analysis of national surveillance data

tetano

Editor, Senior Moderator
J Glob Health


. 2025 Apr 28:15:04141.
doi: 10.7189/jogh.15.04141. Risk factors for severe COVID-19 outcomes in LATAM countries in the post-vaccination era: an analysis of national surveillance data in Argentina, Brazil, Colombia, and Mexico

Guilherme Silva Julian[SUP] #[/SUP][SUP] 1 [/SUP], Júlia Spinardi[SUP] #[/SUP][SUP] 2 3 [/SUP], Melissa Díaz[SUP] 4 [/SUP], Diana Buitrago Ospina[SUP] 4 [/SUP], Nohemi Caballero[SUP] 4 [/SUP], Vinicius Goularte-Silva[SUP] 5 [/SUP], Moe H Kyaw[SUP] 6 [/SUP]



Affiliations
Abstract

Background: Identifying cases at higher risk for severe COVID-19 outcomes is essential for tailoring interventions for prevention and treatment. We aimed to determine the factors related to hospitalisation, intensive care unit (ICU) admission, use of ventilatory support, and mortality in four Latin American countries.
Methods: We conducted a retrospective study using national COVID-19 surveillance databases from Argentina, Brazil, Colombia, and Mexico, covering the period from January 2021 to December 2022. We used multivariate logistic regression models to identify factors associated with hospitalisation, ICU admission, ventilatory support, and death, adjusting for confounding variables.
Results: We included 34 955 384 confirmed cases in the analysis. Age and sex were significantly associated with increased odds of all outcomes. For hospitalisation, in cases aged >85 years, the odds ratio (OR) for hospitalisation ranged from 26.46 (95% confidence interval (CI) = 25.67-27.28) in Mexico to 2763.87 (95% CI = 2644.40-2888.73) in Brazil, and for males, it ranged from 1.42 (95% CI = 1.41-1.43) in Colombia to 1.77 (95% CI = 1.76-1.78) in Brazil. Indigenous race was significantly associated with higher odds of hospitalisation (ORs ranging from 1.26 to 1.98) and death (ORs ranging from 1.05 to 1.84). The number of comorbidities reported was related to increased odds of severe outcomes and varied across countries. The odds of death for cases with zero vaccine doses were significantly higher (ORs ranging from 1.72 to 31.73) compared to cases with two doses. Similarly, the odds of death for cases with one dose were significantly higher (ORs ranging from 1.73 to 7.00) compared to cases with two doses.
Conclusions: Even in a post-vaccine implementation scenario, individual factors such as age, gender, comorbidities, and race still pose a risk to severe COVID-19, which demands tailoring public health strategies for prevention and treatment.


 
Back
Top Bottom